NCT04505618 Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
| NCT ID | NCT04505618 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Johns Hopkins University |
| Condition | Diabetic Retinopathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,050 participants |
| Start Date | 2019-10-01 |
| Primary Completion | 2027-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,050 participants in total. It began in 2019-10-01 with a primary completion date of 2027-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will perform a prospective, longitudinal analysis of clinical and imaging findings from normal controls and subjects with retinal vascular disease to better define the diagnostic imaging criteria that signify change in disease stage. This includes disease progression in early stages of disease or disease regression with appropriate standard-of-care treatment.
Eligibility Criteria
Exclusion Criteria: * Both subjects with diseases and controls: * Children (age\<18) * Pregnant females * Developmentally delayed subjects * Subjects unable to provide informed consent * Inability to cooperate with tests and study instructions * Images with motion artifact or signal strength \< 7 * History of glaucoma * History of age-related macular degeneration * History of any visually significant eye disease * History of proliferative diabetic retinopathy * History of any inflammatory disease * History of heart disease * History of thyroid disease. * Additional criteria for controls: * History of any type of Diabetes Mellitus * History of any type of Hypertension
Contact & Investigator
Amir Kashani, MD, MPH
PRINCIPAL INVESTIGATOR
Johns Hopkins University
Frequently Asked Questions
Who can join the NCT04505618 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Diabetic Retinopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04505618 currently recruiting?
Yes, NCT04505618 is actively recruiting participants. Contact the research team at akashan1@jhmi.edu for enrollment information.
Where is the NCT04505618 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT04505618 clinical trial?
NCT04505618 is sponsored by Johns Hopkins University. The principal investigator is Amir Kashani, MD, MPH at Johns Hopkins University. The trial plans to enroll 1,050 participants.